Reuters logo
BRIEF-Biogen increases profit potential on investigational Alzheimer’S disease treatment
October 24, 2017 / 10:34 AM / 2 months ago

BRIEF-Biogen increases profit potential on investigational Alzheimer’S disease treatment

Oct 24 (Reuters) - Biogen Inc

* Biogen increases profit potential on investigational Alzheimer’S disease treatment Aducanumab through amended agreement with Neurimmune Holding AG

* Makes a one-time $150 million payment to Neurimmune in exchange for a 15 percent reduction in previously negotiated royalty rates​

* ‍Biogen licensed worldwide rights to Aducanumab from Neurimmune in 2007​

* ‍Also has an option to further reduce royalty owed on potential commercial sales of Aducanumab by an additional 5 percent

* Option to reduce royalty owed on potential sales of Aducanumab by 5 percent is in exchange for additional one-time $50 million payment to Neurimmune Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below